ModuleMD Showcases Advanced AI-Driven Allergy Solutions at ACAAI 2025
ORLANDO, Fla., Nov. 22, 2025 /PRNewswire/ -- This November at the ACAAI Annual Meeting 2025, one theme dominated the conversations: AI...
immunotherapy
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD,...
ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform
JERUSALEM, Nov. 20, 2025 /PRNewswire/ -- ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces the...
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S....
Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering...
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platformSAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN...
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiaryPartnership expected to...
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE)...
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free...
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a...
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical...
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is...
LED Operating Light Market Surges to USD 3.2 Billion by 2033, Propelled by 9.2% CAGR – Verified Market Reports®
LED operating light market is experiencing robust expansion driven by rising procedural volumes, growing adoption of minimally invasive surgery, and...
Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics...
Accession Therapeutics doses first patient in Phase 1 clinical trial of TROCEPT-01 (ATTR-01), a novel cancer immunotherapy
OXFORD, England, Nov. 17, 2025 /PRNewswire/ -- Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it...
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive...
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819,...
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE,...
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...